同型半胱氨酸与慢性肾功能衰竭

34-137. 4．Peter WF. Homocysteine andcoronary heart disease how great is the ha zard? JAMA,2002,288:2042-2043. 5．Guttormsen AB, Ueland PM, Faglia G, et al. Kinetic basis of hyperhom ocysleinemia in patient chronic renal failure. Kidney International,199 7,52:495-502. 6．Alessandra F, Perna DI. Possible mechanisms of homocysteine toxicity . Kidney International, 2003,63 suppl 84:137-140. 7．ajiors A Ehrhart LA, Ambrosi B, et al.Homocysteine as a risk factor for vascular disease. Arterioscler Thromb Vasc Biol, 1997,17:2074-2081. 8．路建饶，田军，胡大勇，等. 不同阶段的慢性肾功能衰竭患者血浆同型半胱氨 酸的临床研究. 中华新医学. 2001,4(23):2139-2141. 9．Bostom AG, Shemin D, Lapane KL, et al. Hyperhomocysteinmia and tradi tional cardiovascular disease risk factors in end-stage renal disease p atients on dialysis case-control study. Atherosclosis, 1995, 114:93 10．Bostom AG, Culleton BF. Hyperhomocysteinemia in chronic renal disea se. J Am Soc Nephrol, 1999,10:891-900 11．Liang Min, Yu yue-ming. Homocysteine induces cardiomyocyte hypertro phy and increase intracellular free calcium concentration. Chin J Nephr ol,2003,19:71-73. 12．Bostom AG, Shemin D, Bright TM, et al. Elevated fasting total plasm a homocysteine levels and cardiovascular risk factor in end-stage renal diseases. Arterioscler Throm Vasc Biol,2000,17:2554-2558. 13．Robert C, Sarah L. Homocysteine, renal function, and risk of cardio vascular disease. Kidney International, 2003,63:131-133. 14．Ziad A. Massy. Potential strategies to normalize the levels of homo cysteine in chronic renal failure patients. Kidney International,2003,6 3:134-136. 15．Van Tellingen A, Grooteman MP, Ridgway EC, et al. long-term reducti on of plasma homocysteine levels by super-flux dialyzers in hemodialysi s patients. Kidney Int, 2001,59(1):342-347. 16．Friedman AN, Bostom AG, Ruiz I, et al. Plasma total homocysteine le vels among patients undergoing nocturnal versus standard hemodialysis. J AM Soc Nephrol,2002,13(1):265-268. 17．Ali M, Anjan G, Iwai N, et al. Prevalence and determinants of hyper homocysteinemia in hemodialysis and peritoneal dialysis. Kidney Interna tional,1999,55:1470-1475. 18．Skoupy S, Fodinger M, Ohno T, et al. Riboflavin is a determinant of total homocysteine plasma concentrations in end-stage renal disease pa tients. J Am Soc Nephrol 1,2002,3(5): 1331-1337. 中华综合临床医学杂志

《同型半胱氨酸与慢性肾功能衰竭(第3页)》